ArticleThe Lancet. Oncology2018

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Michael B Atkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.